Lebrikizumab for Eczema in Older Adults: What a 52-Week Multicenter Study Observed

Evidence summary only; systemic treatment decisions require a prescriber.

The evidence gap

Older people with eczema may have different immune biology, comorbidities and medication burdens than the younger adults who dominate clinical trials. A multicenter real-life study evaluated lebrikizumab in an older population for up to 52 weeks.

Reported trajectory

Mean EASI declined from 23.24 at baseline to 6.33 at week 16, 3.57 at week 24 and 2.70 at week 52. The pattern suggests continued improvement among observed patients rather than a plateau at the earliest assessment.

What observational follow-up cannot resolve

Without a concurrent randomized control, improvement can reflect treatment, regression to the mean, background topical therapy and selective continuation. People who stop because of inadequate response, adverse events, access or preference may be missing from later averages. A cohort should report retention and reasons for discontinuation alongside effectiveness.

Biologic safety still needs review

Lebrikizumab targets IL-13. Clinicians consider ocular symptoms, injection reactions, infection history, vaccination and other medical conditions. “Biologic” does not mean risk-free, and older age does not automatically make it preferable to—or unsuitable compared with—another option.

Shared decisions

Useful goals include relief of itch and sleep loss, improved hand or mobility function, fewer flares and a regimen the patient can administer. Vision changes or persistent eye irritation should be reported promptly.

Bottom line

The study provides one-year practice-based evidence for an underrepresented age group. It supports informed discussion but not cross-drug ranking.

Related Dr. Arsy research

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Lebrikizumab in older adults real-world study
2. AAD systemic and phototherapy guideline
3. AAD topical therapy guideline
4. AAAAI/ACAAI GRADE guideline
5. Peer-led online self-management randomized trial
6. Emollient plus versus urea 10% trial
7. Upadacitinib in adults aged 60 years or older
8. Tralokinumab in adults aged 70 years or older
9. Abrocitinib in elderly adults real-world study
10. JAK inhibitors in adults with cardiovascular comorbidity
11. Delgocitinib cream phase 2b trial
12. Ruxolitinib after topical treatment failure trial
13. Mometasone, crisaborole and tofacitinib pilot
14. CAN UpTIMISE after dupilumab study
15. DLLIM international 15,450-patient study
16. REZOLVE-AD phase 2b trial
17. Model-based meta-analysis of 77 studies
18. Targeted-therapy tapering systematic review
19. IL-4 receptor inhibitor meta-analysis
20. Dupilumab SOLO phase 3 trials
21. Tralokinumab ECZTRA 1 and 2 trials
22. Lebrikizumab ADvocate trials
23. Upadacitinib Measure Up trials
24. Abrocitinib JADE MONO-1 trial

Citations do not imply endorsement of #003.